Donna – Car-T Central

Axicabtagene Ciloleucel (Yescarta®) is now publicly funded in Australia for relapsed or refractory DLBCL, PMBCL, TFL and HGBCL

Kite, A Gilead company, have announced that its CAR-T cell therapy, axicabtagene ciloleucel (Yescarta®), is now publicly funded and available for the treatment of patients with relapsed or refractory CD-19 […]

First commercial CAR-T therapy to be manufactured in Australia

Patients with certain blood cancers will benefit from recent approvals for CAR-T therapy to be manufactured in Australia for the first time within the Peter MacCallum Cancer Centre. Australian patients […]

Local delivery of CAR T cells targeting fibroblast activation protein is safe in patients with pleural mesothelioma: first report of FAPME, phase I clinical trial.

https://pubmed.ncbi.nlm.nih.gov/33098996/ Authors: Hiltbrunner S, Bristchgi C, Schuberth P, Bankel L, Nguyen-Kim TDL, Gulati P et al. Ann Oncol 2021;32(1):120-121

Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation.

https://pubmed.ncbi.nlm.nih.gov/32897885/ Authors: Shah GL, DeWolf S, Lee YJ, Tamari R, Dahi PB, Lavery JA et al. J Clin Invest 2020;130(12):6656-6667.

Influence of patient characteristics on chimeric antigen receptor T cell therapy in B-cell acute lymphoblastic leukemia.

https://pubmed.ncbi.nlm.nih.gov/33230103/ Authors: An F, Wang H, Liu Z, Wu F, Zhang J, Tao Q et al. Nat Commun 2020;11(1):5928

Chimeric antigen receptor T-cell therapies in acute myeloid leukaemia

CARs have produced remarkable outcomes in relapsed and refractory B-cell malignancies. However, replicating this success in acute myeloid leukaemia (AML) is not straightforward.

CAR T cell therapy for multiple myeloma

Autologous CAR T cells targeting BCMA are undergoing clinical trials and early results are promising, including in patients who have received a substantial amount of treatment for myeloma over many years and typically do not respond to new therapies.

CAR T cell therapy for solid tumours

The dramatic success achieved using chimeric antigen receptor (CAR) T cells in haematological malignancies has prompted concerted efforts to apply the same technology in solid tumours.

Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis.

https://pubmed.ncbi.nlm.nih.gov/33091355/ Authors: Anagnostou T, Riaz IB, Hashmi SK, Murad MH, Kenderian SS. Lancet Haematol 2020;7(11):e816-e826.

Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial.

https://pubmed.ncbi.nlm.nih.gov/33020647/ Authors: Shah NN, Johnson BD, Schneider D, Zhu F, Szabo A, Keever-Taylor CA et al. Nat Med 2020;26(10):1569-1575.